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Abstract: Prostate cancer (PCa) is the most commonly diagnosed cancer in men. The diagnosis is
currently based on PSA levels, which are associated with overdiagnosis and overtreatment. Moreover,
most PCas are localized tumours; hence, many patients with low-/very low-risk PCa could benefit
from active surveillance (AS) programs instead of more aggressive, active treatments. Heterogeneity
within inclusion criteria and follow-up strategies are the main controversial issues that AS presently
faces. Many biomarkers are currently under investigation in this setting; however, none has yet
demonstrated enough diagnostic ability as an independent predictor of pathological or clinical
progression. This work aims to review the currently available literature on tissue, blood and urine
biomarkers validated in clinical practice for the management of AS patients.
Keywords: prostate cancer; risk predictors; active surveillance; clinical biomarkers
1. Introduction
In 2020, 19.3 million new cases of cancer were diagnosed worldwide, according to
the International Agency for Research of Cancer, of which 1,414,259 were of prostate
cancer (PCa). These figures place PCa in the fourth position in incidence when combining
both sexes, preceded by breast, lung and colorectum cancer [1]. When only men are
considered, PCa represents the second most frequent malignancy after lung cancer (14.1%
and 14.3%, respectively), being considered a global health problem, due to both the volume
of population affected and its economic impact on Health Systems.
Almost 90% of new PCa are localized and they are clinically classified in three risk
groups, based on the serum prostate-specific antigen (PSA) levels, local clinical stage and
histological aggressiveness provided by the Gleason Score (GS): high risk, intermediate risk,
low risk and very low risk [2]. All clinical guidelines, such as European Society of Medical
Oncology (ESMO) [3], National Comprehensive Cancer Network (NCCN) [4] and 2020
EAU-EANM-ESTRO-ESUR-SIOG [5], follow this classification with very little variation.
A recent study, which aimed to characterize PCa features, identified five clinical risk
groups: low-risk localised (LRL), intermediate-risk localised (IRL), high-risk localised
(HRL), positive nodal (N+) and metastatic (M1). Among 635,733 PCa cases analysed,
the overall risk group distribution at diagnosis was: LRL 10.5% (n = 66,959), IRL 49.7%
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(n = 316,227), HRL 34.8% (n = 221 494), N+ 1.5% (n = 9150) and M1 3.5% (21,903). Further-
more, the proportions of patients who died from PCa in the five groups were 3.2%, 5.1%,
10.2%, 19% and 57.2%, respectively [6]
Before active surveillance (AS) appeared, the conventional therapeutic approach was
to offer active treatment, either with surgery or radiotherapy, achieving high cure rates.
However, they are not exempt from side effects at 5 years, including urinary incontinence,
erectile dysfunction and bowel toxicity [7].
PCa occupies the fifth position in terms of mortality, with 375,304 cases in 2020
worldwide, preceded by lung, liver, stomach and colorectal cancers [1]. This difference
between incidence and mortality is due to both the favourable impact of the treatments
and the heterogeneous aggressiveness of these tumours. Furthermore, PCa has a slow
evolution, even latent, and most tumours are diagnosed well before they are considered
as clinically significant PCa (csPCa), characterized by International Society of Urological
Pathology (ISUP) histopathology grade ≥2 and/or volume ≥0.5 cc and/or extraprostatic
extension [8]. In fact, one-third of screening-detected PCa never becomes a health problem.
Reinforcing this evidence, it is well known that 59% of necropsies of men over 79 years of
age who died from other causes have latent PCa [9].
The effects of overdiagnosis, a consequence of current diagnostic pathways, could be
minimized by progressive improvements in the characterization of indolent PCa, as well
as, the implementation of less aggressive therapeutic strategies such as AS, with promising
results after long follow-up, of up to 8 years [10].
In only a decade, AS has moved from uncertainty and low acceptability among
urologists to representing the first therapeutic option in every clinical guideline [4,5] for
very low/low risk and even some de novo intermediate-risk tumours [3,11]. However, the
trend today is that AS protocols should pursue the reduction of strict follow-up biopsy
schemes [12], and personalised biopsy schedules have been proposed based on the risk
of Gleason upgrading. This reduction could also be favoured by improving the selection
of low-risk PCa both with biomarkers or multiparametric magnetic resonance imaging
(mpMRI) [13].
The new taxonomic classification of PCa in seven molecular biotypes has given some
light to the biologic and molecular characterization of such a heterogeneous disease, but
it is still far from changing daily practice [14]. AS has evolved with the refinement of
imaging, where multiparametric magnetic resonance imaging (mpMRI) has been key, but
it is still limited when used alone for clinical decision-making, together with its availability,
cost and dependency on the radiologists experience as collateral drawbacks [15,16]. We
have focused on commercially available biomarkers for AS management in our review,
although we recognize that mpMRI is already an established tool that has optimized AS
management; hence, potential synergies between mpMRI and some biomarkers have also
been addressed.
As mentioned above, biomarkers would constitute our second tool. They should
“scan” the whole prostate and be widely available, reproducible, inexpensive, objective
and with adjusted predictions. However, these are characteristics that not all biomarkers
demonstrate, and the search continues to find the “ideal biomarker”, the “Holy Grail”
studying serum, urine or prostatic tissue [17,18]. Knowing that the molecular classification
of PCa will probably pave the road for more specific biomarkers in different molecular
biotypes, the aim of this study is to review the present literature in clinically available
biomarkers that could help to optimize AS in daily practice.
2. Evidence Acquisition
A comprehensive literature search from January 2013 to March 2021 was performed
in PubMed, including articles written in English language, reporting on PCa diagnosis and
follow-up biomarkers. A specific search strategy was designed combining the following
keywords: “prostate cancer”, “active surveillance”, “tissue biomarkers”, “blood biomark-
ers”, “urine biomarkers” and “clinical significance”. In particular, the following search
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blocks were used for the PubMed database (active surveillance) AND (prostate cancer)
AND (biomarker) AND [(tissue) OR (blood) OR (urine)] AND (clinical significance). Due to
the exigent search criteria used, mainly based on the addition of the “clinical significance”
label, secondary sources were also examined in a descriptive manner. Cross-referenced
potentiality relevant articles, not identified in the primary search, were also considered and
hand-picked. Case reports, editorials, letters, congress abstract and congress communica-
tions were not eligible.
Original research articles were curated based on favouring large sample sizes, inde-
pendent validation and patients directly included in AS programs and not just as per its
role in optimizing PCa diagnosis. When biomarkers were studied in diagnosis, we focused
our interest in those cohorts already in AS and its role in its clinical management. All
abstracts were reviewed by expert urologists (J.R.-B., A.B.-F., J.L.D.-E.).
After exclusion of duplicates and articles unrelated to the topic of this review, 267 full-
text records were screened, and finally, 26 papers accomplished final eligibility. Then, 39
other papers were added that focus on commercially available markers related to the topic.
The article selection process is shown in a workflow diagram (Figure 1).
Figure 1. Workflow diagram of the references’ selection process. Bibliography was selected considering different sources of




Nobody questions the role of PSA in PCa screening, with the latest publication of
the European Randomized Screening in Prostate Cancer setting its irreplaceable impor-
tance [19]. However, once diagnosed, in those PCa candidates for AS, its role as biomarker
has been questioned due to its variability and has been preferably studied related to its
changes with time, prostate volume or other isoforms.
# PSA kinetics
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Diagnostic and follow-up of PCa patients based on PSA measurements are still the
most common strategies, although PSA has been demonstrated as an unspecific biomarker
in the AS setting. The rate of PSA change over time, known as PSA dynamics or kinetics
(PSAk), was conceptually introduced by Carter in 1992 [20]. PSAk has been shown to over-
come PSA limitations and to predict PCa reclassification in men enrolled in AS programs.
Cooperberg et al., calculated PSAk using a linear mixed-effect model, in which the
natural logarithm of PSA (ln[PSA]) was modelled as a linear function of time since the
diagnosis, with a random intercept indicating the individual-specific ln[PSA] at diagnosis
and a random slope reflecting the individual-specific rate of change over time. It was
tested in a multicentre cohort with long-term follow-up, suggesting that collecting PSA
measurements over time could be clinically useful at predicting outcomes in men with PCa
on AS [21].
Related to PSAk, PSA doubling-time (PSADT) is the number of years over which a
certain level of PSA increases by a factor of two and is calculated as DT = ln(2)/m, where
m is the slope of the regression of ln[PSA] over time [22]. In the prospective multicentre
Canary Prostate Active Surveillance Study (PASS), PSADT < 36 months was originally a
criterion for progression, and some authors recommended this parameter for the detection
of aggressive tumours during AS [23]. However, it was found to be unspecific [24] and
must be evaluated as a part of the PSAk linear model.
On the other hand, PSA velocity (PSAV) represents a change in PSA level over time
and is calculated by linear regression of untransformed PSA values. By calculating the
number of times that serial PSAV measurements pass a threshold, Patel et al. developed
the PSAV Risk Count (PSAV RC) score. When used in a cohort of very low-risk PCa, it
was associated with an increased risk of biopsy reclassification due to any unfavourable
pathology finding; hence, PSAV RC is proposed for monitoring patients on AS and to
decrease the frequency of biopsies in the long term [25].
In summary, higher PSAV and shorter PSADT kinetics might be useful in differentiat-
ing between PCa with more aggressive potential. The association between pre-treatment
PSAk and PCa biology is supported by multiple studies that found a strong association
between the PSAV and PSADT and various pathological features of aggressive PCa [22].
# PSA density (PSAD)
The PSA density (PSAD), calculated by dividing the preoperative PSA by the prostate
volume (without seminal vesicles), was introduced in the early 1990s by Benson et al. [26].
Its role in predicting upgrading and reclassification in men with low-risk PCa enrolled in
AS has been assessed in several studies.
A study recently published by Yusim et al. including 992 men with a median age
of 66 years concluded that patients with PSAD higher than 0.34 ng/mL2 have a 56.4%
chance of being diagnosed with a csPCa, with risks estimated at 4%, 8.5% and 31.5%, for
PSADs <0.09 ng/mL2, between 0.09 and 0.19 ng/mL2 and between 0.19 and 0.34 ng/mL2,
respectively [27]. Moreover, it has been demonstrated that PSAD values differ between
African American (AA) men and Caucasian men, being lower in AA patients in cases of
similar tumour volumes [28].
In summary, PSAD is proposed to be tested prior to prostate biopsy as it is an inex-
pensive and widely available tool, which may avoid unnecessary biopsies. Its inclusion in
AS protocols could improve inclusion criteria and follow-up of PCa patients. Furthermore,
the more accurate prostate volume calculation by MRI might potentially make its use more
reliable [27,29].
# Prostate Health Index (PHI)
PHI, from Beckman Coulter [30], is a diagnostic blood test that combines free (fPSA),
total PSA (tPSA) and isoform [-2]proPSA into a single score, calculated according to the
formula [-2]proPSA/fPSA x
√
tPSA, developed to maximize specificity at high sensitiv-
ity [31]. Approved by the USA Food and Drug Administration (FDA), it is now considered
by the NCCN guidelines in the diagnostic setting [4].
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Chiu et al., demonstrated that PHI and %p2PSA are predictors of RP pathologic
outcomes such as pT3, pGS, GS upgrade, tumour volume >0.5 mL, and Epstein criteria
for significant tumours [32]. Moreover, Hirama et al. showed the high diagnostic ability
of p2PSA-related parameters, such as %p2PSA and PHI, for discriminating patients with
non-significant cancer from those with significant cancer, being useful markers for AS [23].
Several studies compared the predicting value of PHI and PCA3. Cantiello et al.,
found a superior predictive accuracy of PHI over PCA3 (AUC 0.92 vs. AUC 0.77) in
discriminating clinically significant disease in men eligible for AS, outperforming PCA3
performance, resulting in a higher net benefit [33,34].
The use of these markers may reduce the incidence of underestimation at initial diag-
nosis, enabling a more accurate selection of candidates suitable for AS. PHI measurement
could be clinically useful in discriminating the presence of insignificant PCa in AS candi-
dates [23,31–33]. Furthermore, its utility is increased by adding mpMRI to discriminate
the presence of pathologically confirmed significant PCa, as demonstrated in a cohort of
patients who underwent RP but were eligible for AS [35].
# 4Kscore®
The 4Kscore® is a prebiopsy blood test developed by OPKOlab that incorporates a panel
of four kallikreins (tPSA, fPSA, intact PSA [iPSA] and human kallikrein 2 [hK2]) combined
with clinical features such as the 4Kscore®, which determines a man’s risk for high-grade
aggressive PCa (GS ≥ 7) [36], improving decision making regarding prostate biopsy.
The 4Kscore® provides a score ranging from 0 to100%, reflecting the probability of
finding a significant PCa at biopsy; hence, 100% minus the 4Kscore result is the personal-
ized negative predictive value (NPV) or probability that a patient will not have Gleason
≥7 cancer on prostate biopsy [37].
Lin et al. evaluated the 4Kscore® in a cohort of patients candidates for AS, already
diagnosed with cancer, demonstrating that the addition of 4Kscore® to a model contain-
ing clinical information significantly improves the prediction of the outcome in the first
surveillance biopsy, which is associated with reclassification [38].
Similarly, in a prospective evaluation by Borque-Fernando et al. in an AS scenario,
concluded that the 4Kscore®, at a cut-off 7.5%, was significantly associated with tumour
reclassification at the confirmatory biopsy, while the previously used %fPSA/tPSA ratio
did not show this association [39].
Due to the ability of the 4Kscore® to discriminate between men who are likely to
harbour clinically relevant PCa and those with indolent tumours or no cancer, it has been
proposed as a good marker to identify patients who are more likely to benefit from biopsy,
due to a higher risk of csPCa requiring active treatment [39,40] potentially implemented in
an AS setting [37–41].
3.2. Tissue Biomarkers
# Oncotype DX® Genomic Prostate Score (GPS)
The Oncotype Dx® Genomic Prostate Score (GPS), from Genomic Health® [42], is
an RNA based expression assay that includes 12 PCa related genes normalized to five
housekeeping genes, which can be performed on needle core biopsy tissues. This test
uses real-time quantitative polymerase chain reaction (RT-qPCR) to measure expression
levels of genes related to four tumour aggressiveness pathways, including androgen
signalling (AZGP1, KLK2, SRD5A2, and FAM13C), cellular organization (FLNC, GSN,
TPM2, and GSTM2), stromal response (BGN, COL1A1, and SFRP4) and cellular proliferation
(TPX2) [43].
GPS has been shown to predict adverse surgical pathology (AP) and biochemical
recurrence (BR) in men diagnosed with low- and intermediate-risk PCa treated with
immediate surgery [44,45]. It has been used as a tool to inform the decision making
of immediate treatment versus AS in men newly diagnosed with low- or favourable
intermediate-risk PCa and was recently included in the NCCN guidelines [46]. Some
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studies have demonstrated that GPS is associated with an increased risk of AP findings in
AS patients who later underwent radical prostatectomy (RP), being also associated with
BR following surgery in such patients [46,47]. The GPS ranges from 0 to 100, with higher
scores indicating a greater risk of aggressive disease.
Eure et al. reported higher rates of AS uptake (62% vs. 40%) and persistence on AS at
1 year (55% vs. 35%) among men who underwent the GPS testing compared to those who
did not [48]. The GPS test has been recommended in men with early-stage PCa [49]. In
this way, after obtaining a GPS, more patients were re-classified as very low-risk compared
to the initial distribution determined by the NCCN risk category alone [42]. Regarding
reproducibility, the initial test is the most informative, and serial testing seems to have
limited benefit [43].
Although higher GPS has been associated with an increased risk of AP and BR, it
is reasonable to use the GPS in conjunction with other known clinical risk factors when
selecting patient candidates for AS [47].
# Genome DX Decipher® Genomic Classifier
Decipher® Prostate Cancer Test, from Genome Dx Biosciences [50], is a 22-feature
RNA biomarker assay that has been developed to predict metastasis risk at 5- and 10-years
after RP [51]. This test incorporates 22 coding and non-coding genes that cover seven
cancer pathways, including angiogenesis, invasion and metastasis, or growth and differ-
entiation [50]. It generates a score ranging from 0 to 1, with higher values indicating an
increased probability for both AP and poorer oncologic outcomes [52].
Decipher® is a significant predictor of AP when used alone or combined with clinical
risk stratification systems [53], and when applied to prostatectomy tissue from NCCN very
low-/low- and favourable intermediate-risk patients, it has identified patients inappropri-
ately selected for AS.
It has been demonstrated that Decipher® at the biopsy cores outperformed NCCN
clinical risk grouping, biopsy GS and preoperative PSA; for every 10% increase in the
Decipher® score, the high-risk increased by 1.72 [53]. Notably, combining Decipher® with
NCCN risk groups increased the concordance index (C-index) from 0.75 to 0.88, suggesting
that Decipher® captures a considerable proportion of PCa available on diagnostic needle
biopsies obtained in routine clinical practice. Decipher® scores on biopsies were also
predictive of other key outcomes, including the presence of primary Gleason pattern 4/5
and an elevated risk of metastasis within 5 years [54]. Applying the Decipher ® test appears
to better guide treatment recommendations [55].
# Prolaris® (Cell Cycle Progression Score)
The Cell Cycle Progression (CCP) score, from Myriad [56], is a validated prognostic
RNA expression signature, based on the expression levels of 31 genes related to cell cycle
progression and 15 housekeeping genes. Several studies have demonstrated that the CCP
score is strongly associated with progression to metastatic disease after both surgery and
radiotherapy [57–59].
The CCP score threshold was developed in men who might typically be considered
for AS based on having low- or favourable intermediate-risk disease according to a con-
servative interpretation of NCCN guidelines [46]. The combination of CCP score with
clinico-pathologic risk factors from the Cancer of the Prostate Risk Assessment (CAPRA)
model [60] results in the cell cycle risk (CCR) test, with a better classification performance.
The CCR-based risk stratification might guide the identification of patient candidates to
AS from those who would require more active intervention [58]. Both the molecular score
and the derived predicted risk might be used in both AA and non-AA patients with newly
diagnosed PCa [59].
Lin et al., validated this test in conservatively managed men and showed that the CCR
score threshold significantly dichotomized men with high-risk (CCR >0.8) and low-risk
(≤0.8) of 10-year PCa mortality, indicating that the threshold can be safely used to identify
candidates for AS. Application of the CCR score threshold should result in a substantial
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increase in men who would be considered candidates for AS that would have traditionally
been excluded [57].
3.3. Urine Biomarkers
# Prostate Cancer Antigen 3 (PCA3)
PCA3 was first described in 1999 by Bussemakers et al. [61] as a non-coding mRNA
only expressed in human prostate tissue but significantly overexpressed in PCa and is
used in clinical practice as Progensa® PCA3 assay, an in vitro nucleic acid amplification
test, developed by Hologic [62], approved by the FDA to be used in conjunction with other
patient information to aid the decision for repeat biopsy in men 50 years of age or older
with one or more previous negative prostate biopsies.
This PCA3 score is generated as a ratio of PCA3 mRNA to PSA mRNA in urine
multiplied by 1000, and a PCA3 score <25 is associated with a decreased likelihood of
positive biopsy [63,64].
Tosoian et al., evaluated it in a cohort of men with favourable-risk PCa included in AS
programs and who underwent tumour reclassification, demonstrating that patients who
reclassified had significantly higher PCA3 scores at both initial (48.0 vs. 24.5, p = 0.007)
and subsequent (63.5 vs. 36.0, p = 0.002) measurements, indicating an association between
PCA3 and grade reclassification [65].
However, despite the demonstrated PCA3 utility for PCa diagnosis, several studies
suggest that additional biomarkers should be incorporated into PCA3 to ensure detection
of high grade [66].
The addition of mpMRI to PCA3 reduces overdetection and overtreatment of indolent
PCa by improving diagnostic accuracy. Hence, the use of urinary PCA3 testing in men with
low or equivocal suspicion mpMRI allows unnecessary biopsies, the refinement of risk
stratification and the optimization of high-grade cancer detection to be reduced [64].
# TMPRSS2:ERG (T2E) fusion gene
The T2E fusion gene was first discovered in 2005 by Tomlins et al. [67], and it is
present in approximately 50% of PCas. It constitutes a highly specific biomarker that can
be detected both in FFPE and urine samples [68,69].
In a prospective study by Lin et al., post-digital rectal examination (post-DRE) urine
samples were collected and T2E levels were analysed, indicating an association with
higher tumour volume and higher GS in subsequent biopsies [70]. Furthermore, high T2E
expression levels have been associated with an increased risk of tumour upgrading and
upstaging in AS candidates [71].
In an AS context, Whelan et al., assessing the effectiveness of T2E expression in
prostatic secretions, showed that non-invasive T2E measurement in urine may refine
patient acceptance into AS programs [72].
However, a comparative study between urinary PCA3 and T2E measures during multiple
times at surveillance found that these markers add little or no improvement in clinical variables
in predicting biopsy reclassification due to the high PCa heterogeneity [73,74]. Hence, both
PCA3 and T2E are proposed to be combined in a risk calculator, MiProstate Score (MiPS),
which shows higher specificity and sensitivity [75,76].
# SelectMDx
Related to urinary biomarkers useful in predicting csPCa, a novel urinary assay-based
risk score called SelectMDx from MDXHealth® was developed by combining serum PSA,
PSAD and clinical factors such as age and prior negative biopsy with two mRNA signatures,
namely urinary homeobox C6 (HOXC6) and distal-less homeobox 1 (DLX1), and KLK3
gene as a reference [77].
Leyten et al. developed the test based on detecting increased mRNA levels HOXC6,
DLX and tudor-domain-containing 1 (TDRD1), which have been selected between eight
candidates because of having independent additional predictive value of PSA for the
detection of biopsy GS ≥7. These genes have been associated with PCa development [78].
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In this study, it was shown that the combination of urinary HOXC6 and DLX1 was superior
to Progensa® PCA3 in the diagnosis of GS ≥ 7 PCa.
Based on the urinary biomarker panel previously defined, Van Neste et al. proposed a
new test by combining HOXC6 and DLX1 mRNA expression levels with traditional clinical
risk factors, such as PSAD, DRE, PSA, age, history of prostate biopsy and family history,
which is able to detect high-grade csPCa accurately and consequently could be used in AS
decision making, reducing unnecessary biopsies and potential overtreatment [79].
We have just published our results with SelectMDx and PCA3 in an AS setting, show-
ing that SelectMDx showed statistically significant differences related to pathological
progression-free survival (HR: 1.035; 95% CI: 1.012–1.057) (p = 0.002) with a C-index of
0.670 (95% CI: 0.529–0.810) and AUC of 0.714(95% CI: 0.603–0.825) at 5 years. The combi-
nation of both biomarkers did not improve the prediction of PP and C-index 0.630 (95%
CI: 0.455–0.805) [80]. Despite the high ability of SelectMDx in predicting the likelihood
of finding high-grade PCa, it has been demonstrated that its combination with mpMRI
could better select candidates to AS, identifying men who harbour csPCa, hence improv-
ing the cost-effectiveness. Pepe P et al., found that mpMRI and SelectMDx missed 3/9
(33.3%) and 4/9 (44.5%) of csPCa, respectively. Moreover, mpMRI combined with Select-
MDx diagnosed 7/9 (77.8%) csPCa, outperforming SelectMDx alone, in a cohort of men
enrolled in an AS protocol [81,82]. Nonetheless, several studies have demonstrated the
potential cost-effectiveness of SelectMDx alone and instead of using mpMRI. In Spain,
the cost-saving result of using the SelectMDx strategy has been estimated at EUR 247 per
patient, which is EUR 20 million per yearly cohort, mostly by preventing the detection
of insignificant cancers and, to a lesser extent, by reducing the number of biopsies [83].
Similarly, Dijkstra et al. showed that SelectMDx could improve PCa patients’ quality of
life and detect high-grade tumours while saving cost compared to the current standard of
care [84].
4. Conclusions
Active Surveillance (AS) is increasingly used in all health systems, balancing screening
benefits with lowering overtreatment in PCa. Since this strategy was introduced, AS
has evolved from initial protocols a decade ago, allowing inclusion without any reliable
imaging, to more refined contemporary management pathways, guided by mpMRI imaging
and fusion biopsy. Nevertheless, mpMRI is not widely available everywhere, and it is still
very dependent on radiologist expertise and hence lacks homogeneity.
Biomarkers might play a role, probably combined with mpMRI and mainly in PIRADs
3 lesions, the “grey box”, where results are unclear. Their potential to give information from
the scan the whole gland, their homogeneity, reproducibility and potential for comparison
make them very attractive in the AS setting, but their prices should come down in order to
be generalized, mainly tissular, markers. Most of them have shown in pilot studies their
complementary role with mpMRI, but none is going to replace it when a biopsy is needed,
at both the confirmatory and follow-up phases.
The main limitation that we have found in this review is that there are few studies
specifically focused on applying these biomarkers in AS series. However, given the
applicability that many of these tests have in identifying csPCa, they are good candidates
for being tested in an AS scenario (Table 1).
Tissular biomarkers, mainly those analysing independent molecular markers not
related to classical clinic-pathological variables, could have a role in the future of AS
management. However, issues in terms of high costs and difficulties in handling are
drawbacks that should overcome before widespread implementation is possible. Therefore,
at present, we can just recommend them in doubtful cases such as high-volume Gleason 3
+ 3 or favourable intermediate-risk PCa where a more conservative management could be
considered in case of favourable tissular marker scoring.
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Table 1. Summary of clinically available biomarkers and tests with AS application.
Biomarker Source Characteristics AS Application References
PSA Blood
PSA is a glycoprotein secreted by
prostatic epithelial cells that lyses the
clotted ejaculate to enhance sperm
motility. It is the most important
commonly used biomarker, but it has
been shown not to be a cancer-specific
marker, as some prostate diseases could
also produce PSA elevated levels
Its role as biomarker in AS has been
questioned due to its variability and has
been mostly studied related to its




Rate of PSA change over time: PSA
doubling time (PSADT) is the number of
years over which a certain level of PSA
increases by a factor of two and is
calculated as DT = ln(2); PSA velocity
(PSAV) represents a change in PSA level
over time/m
Differentiates between PCa with more
and less aggressive natural history [20–25]
PSA density (PSAD) Blood Dividing preoperative PSA by prostateweight without seminal vesicles
Predicts upgrading and reclassification in
men with low-risk PCa enrolled in AS,
by improving the inclusion criteria and








PHI measurement could be clinically
useful in discriminating the presence of




A panel of four kallikreins (tPSA, fPSA,
intact PSA [iPSA], and human kallikrein
2 [hK2]) combined with clinical data
available before cancer diagnosis
Identifies patients most likely to benefit
from biopsy because of a high risk of
having a clinically significant tumour





RNA based expression assay of 12 PCa
related normalized to
5 housekeeping genes
Associated with an increased risk of AP






Includes 22 coding and non-coding
genes, which covers seven cancer
pathways, such as angiogenesis, invasion
and metastasis, or growth
and differentiation
Helps to predict metastasis risk after RP






RNA expression signature based on
measuring the expression levels of 31
genes that participate in cell cycle
progression and 15 housekeeping genes
Helps to identify patients who may
warrant increased intervention intensity





Non-coding mRNA only expressed in
human prostate tissue but overexpressed
in PCa tissue
Patients who reclassified had
significantly higher PCA3 scores at both
initial and subsequent measures,





T2E fusion gene is present in
approximately 50% of prostatic tumours
and is detected both in FFPE and
urine samples
Non-invasive T2E measurement in urine




Combines serum PSA, PSAD and clinical
factors such as age and prior negative
biopsy with mRNA signatures: urinary
homeobox C6 (HOXC6) and distal-less
homeobox 1 (DLX1)
Can detect high-grade csPCa accurately
and could therefore be used in AS
decision making, reducing the number of
unnecessary prostate biopsies and
potential overtreatment
[78–85]
Prospective and longitudinal studies with different biomarkers focused on AS cohorts
are still missing. Prospective, well-designed studies assessing predefined clinically relevant
endpoints are needed to fully assess the real potential of these biomarkers and to compare
them with other diagnostic tools, such as novel predictors of grade progression and mpMRI-
PRECISE criteria [85]. Robust clinical evidence derived from such studies will support and
guide clinical decision-making in the selection, management and long-term follow-up of
PCa patients in AS schemes.
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